Teva launches authorized Cubicin generic

JERUSALEM — Teva on Thursday announced the U.S. launch of its authorized generic of Cubicin (daptomycin for injection).  The drug is indicated to treat complicated skin and skin structure infections staphylococcus aureus, streptococcus pyogenes, streptococcus dysgalactiae subspecies equisimiis and enterococcus faecalis. 

 

The drug had about $1.2 billion in U.S. sales as of July 2016, according to IMS Health data. The authorized generic will be sold in vials of 500 mg.